Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Rezolute, Inc. Director's Dealing 2014

Jul 24, 2014

32362_dirs_2014-07-24_ac481fa1-7b0a-4f03-b142-2136dfe622b8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AntriaBio, Inc. (FMYY)
CIK: 0001509261
Period of Report: 2014-07-18

Reporting Person: Fields Morgan (Chief Accounting Officer)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Option to purchase Common Stock $4.50 2018-06-04 Common Stock (4167) Direct
Option to purchase Common Stock $3.12 2021-03-26 Common Stock (110000) Direct
Option to purchase Common Stock $1.84 2021-07-18 Common Stock (25000) Direct

Footnotes

F1: Pursuant to the terms of the Reporting Person's option to purchase common stock ("Common Stock Option I"), 25% of the Common Stock Option I vested on each of June 4, 2013, October, 29, 2013 and April 29, 2014, the remaining 25% of the Common Stock Option I will vest on October 29, 2014.

F2: Pursuant to the terms of the Reporting Person's option to purchase common stock ("Common Stock Option II"), 1/48th of the Common Stock Option II vested on each of April 30, 2014, May 31, 2014 and June 30, 2014, the remaining Common Stock Option II will vest monthly over the forty-five months thereafter.

F3: Pursuant to the terms of the Reporting Person's option to purchase common stock ("Common Stock Option III"), 1/48th of the Common Stock Option III will vest on August 31, 2014, with the remaining Common Stock Option III to vest monthly over the forty-seven months thereafter.